Drug intelligence / Profile preview

Admax

Development stage: Unknown
Lead developer: Zuventus Healthcare
Modality: Small Molecules
Administration: Oral

Overview

**Admax** is a marketed oral fixed-dose calcium and vitamin D mineral-supplement product from Zuventus. Each soft-gelatin capsule contains calcium carbonate providing 400 mg elemental calcium, calcitriol 0.25 mcg, and zinc 7.5 mg as zinc sulfate monohydrate. Calcitriol activates the vitamin D receptor to increase intestinal calcium absorption, while calcium and zinc support bone mineralization. The product is used for calcium deficiency and supportive management of bone disorders including osteoporosis. ([zuventus.com](https://www.zuventus.com/products/admax-capsules))

Brand names: Admax

Targets

VDR (Vitamin D receptor)

Beyond the preview

Go deeper on Admax.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Admax.

Explore the full profile